You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Alectinib

Showing 1 - 25 of 79
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial (food, fast)

Not yet recruiting
  • NSCLC
  • food
  • fast
  • (no location specified)
Jan 24, 2023

NSCLC Stage IIIB, ALK Gene Mutation Trial in Mexico City (Alectinib Oral Product)

Recruiting
  • Non-small Cell Lung Cancer Stage IIIB
  • ALK Gene Mutation
  • Alectinib Oral Product
  • Mexico City, Mexico
    Thoracic Oncology Unit and Personalized Medicine Laboratory, Ins
Jan 26, 2023

Radiotherapy Side Effect, NSCLC, ALK Gene Mutation Trial in Stockholm (SBRT/SRS/radiation therapy)

Not yet recruiting
  • Radiotherapy Side Effect
  • +2 more
  • SBRT/SRS/radiation therapy
  • Stockholm, Sweden
    Karolinska University Hospital
Feb 16, 2023

Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer

Active, not recruiting
  • Non-Small-Cell Lung Carcinoma
  • Alectinib
  • New York, New York
    Pfizer Inc
Apr 12, 2022

Lung Cancer, NSCLC, Brain Metastases Trial (Alectinib, Stereotactic Radiosurgery)

Not yet recruiting
  • Lung Cancer
  • +2 more
  • Alectinib
  • Stereotactic Radiosurgery
  • (no location specified)
Aug 4, 2023

NSCLC, NSCLC Metastatic, NSCLC Recurrent Trial in Worldwide (Alectinib)

Terminated
  • Non-small Cell Lung Cancer
  • +2 more
  • Alectinib
  • Brussels, Belgium
  • +18 more
Aug 23, 2022

ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Trial in Changsha (Pembrolizumab Combined With Bevacizumab and

Not yet recruiting
  • ALK Gene Mutation
  • +2 more
  • Pembrolizumab Combined With Bevacizumab and Chemotherapy
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Jul 14, 2022

ALK Fusion-positive Solid or CNS Tumors Trial in Worldwide (Alectinib)

Recruiting
  • ALK Fusion-positive Solid or CNS Tumors
  • Alectinib
  • New York, New York
  • +17 more
Jul 25, 2022

Non Small Cell Lung Cancer Trial in Changsha (IBI-322 Plus Lenvatinib and Platinum)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • IBI-322 Plus Lenvatinib and Platinum
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 14, 2022

ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer (NSCLC)
  • +2 more
  • Alectinib
  • Irvine, California
  • +3 more
Aug 30, 2021

Cancer Medicines in Metastatic Non-small Cell Lung Cancer in

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Oslo, Norway
    Pfizer Norway
Apr 17, 2023

Solid Tumor, Haematological Malignancy, Malignant Tumor Trial in United Kingdom (Alectinib)

Recruiting
  • Solid Tumor
  • +10 more
  • Alectinib
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Metastatic Colorectal Cancer Trial in Oslo (Alectinib, Cetuximab, Crizotinib)

Recruiting
  • Metastatic Colorectal Cancer
  • Alectinib
  • +16 more
  • Oslo, Norway
    Oslo University Hospital
Feb 10, 2023

Chemotherapy Combined With Immunotherapy or Chemotherapy

Completed
  • Non-small Cell Lung Cancer
  • Alectinib
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 9, 2022

NSCLC Trial in London (MPDL3280A, Vemurafenib, Alectinib)

Recruiting
  • Non-small Cell Lung Cancer
  • London, United Kingdom
    Univeristy College London Hospital
Feb 22, 2022

Metastatic or Locally Advanced Malignancies Trial in Germany (Vemurafenib, Cobimetinib, Atezolizumab)

Recruiting
  • Metastatic or Locally Advanced Malignancies
  • Berlin, Germany
  • +5 more
Jan 2, 2023

Tumors, Colorectal Tumors, Melanoma Trial in United States (Alectinib)

Terminated
  • Neoplasms
  • +27 more
  • Alectinib
  • Culver City, California
  • +28 more
Jul 25, 2022

NSCLC Trial in Boston (Alectinib, Cobimetinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Boston, Massachusetts
    Massachusetts general Hospital
Mar 7, 2021

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

free Survival and Evaluate Participant Experience for Metastatic

Active, not recruiting
  • Anaplastic Lymphoma Kinase-positive
  • Carcinoma Non-small-cell Lung
  • Maynard, Massachusetts
    EmpiraMed, Inc.
Feb 28, 2022

Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese

Completed
  • ALK-positive Non-small-cell Lung Cancer
  • Nagoya, Aichi, Japan
  • +15 more
Jan 31, 2022

Cancer, Tumors, Tumors Trial in Denmark (Alectinib, Atezolizumab, Avelumab)

Recruiting
  • Cancer
  • +3 more
  • Alectinib
  • +9 more
  • Aalborg, Denmark
  • +6 more
Oct 25, 2022

ALK Translocations in Serial Blood Samples From Non-Small Cell

Enrolling by invitation
  • Lung Cancer
  • +3 more
  • Alectinib
  • Aarhus, Denmark
    Aarhus University Hospital
Jan 30, 2021

ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Tumor of Lung Trial in Mexico City (Alectinib, Bevacizumab)

Unknown status
  • ALK Gene Rearrangement Positive
  • Non-Squamous Non-Small Cell Neoplasm of Lung
  • Mexico City, Mexico
    Instituto Nacional de Cancerologia
Feb 8, 2021

Advanced Cancer, Solid Tumor Trial in Helsinki, Kuopio, Tampere (Alectinib, Cobimetinib, Vismodegib)

Recruiting
  • Advanced Cancer
  • Solid Tumor
  • Alectinib
  • +13 more
  • Helsinki, Uusimaa, Finland
  • +2 more
Jun 8, 2022